AMAG Pharmaceuticals, Inc. (AMAG) EPS Estimated At $0.09; Shorts at Monarch Casino & Resort (MCRI) Lowered By 3.75%

January 14, 2018 - By Richard Conner

Analysts expect AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) to report $0.09 EPS on February, 13.They anticipate $0.40 EPS change or 129.03% from last quarter’s $-0.31 EPS. AMAG’s profit would be $3.18M giving it 40.00 P/E if the $0.09 EPS is correct. After having $1.57 EPS previously, AMAG Pharmaceuticals, Inc.’s analysts see -94.27% EPS growth. The stock increased 0.35% or $0.05 during the last trading session, reaching $14.4. About 442,122 shares traded. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has risen 3.00% since January 14, 2017 and is uptrending. It has underperformed by 13.70% the S&P500.

Monarch Casino & Resort Incorporated (NASDAQ:MCRI) had a decrease of 3.75% in short interest. MCRI’s SI was 261,900 shares in January as released by FINRA. Its down 3.75% from 272,100 shares previously. With 103,700 avg volume, 3 days are for Monarch Casino & Resort Incorporated (NASDAQ:MCRI)’s short sellers to cover MCRI’s short positions. The SI to Monarch Casino & Resort Incorporated’s float is 2.54%. The stock increased 0.20% or $0.09 during the last trading session, reaching $45.42. About 30,469 shares traded. Monarch Casino & Resort, Inc. (NASDAQ:MCRI) has risen 53.31% since January 14, 2017 and is uptrending. It has outperformed by 36.61% the S&P500.

Monarch Casino & Resort, Inc., through its subsidiaries, owns and operates the Atlantis Casino Resort Spa, a hotel/casino facility in Reno, Nevada; and the Monarch Casino Black Hawk in Black Hawk, Colorado. The company has market cap of $803.96 million. As of February 22, 2017, its Atlantis Casino Resort Spa featured approximately 61,000 square feet of casino space; 824 guest rooms and suites; 8 food outlets; 2 espresso and pastry bars; a 30,000 square foot health spa and salon with an enclosed year-round pool; 2 retail outlets offering clothing and traditional gift shop merchandise; an 8,000 square-foot family entertainment center; and approximately 52,000 square feet of banquet, convention, and meeting room space. It has a 29.88 P/E ratio. The companyÂ’s Atlantis Casino Resort Spa also featured approximately 1,450 slot and video poker machines; approximately 38 table games, including blackjack, craps, roulette, and others; a race and sports book; a 24-hour live keno lounge; and a poker room.

Among 3 analysts covering Monarch Casino & Resort (NASDAQ:MCRI), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Monarch Casino & Resort had 3 analyst reports since December 8, 2015 according to SRatingsIntel. The company was upgraded on Wednesday, October 25 by Union Gaming. As per Friday, October 14, the company rating was initiated by Gabelli. The stock of Monarch Casino & Resort, Inc. (NASDAQ:MCRI) has “Buy” rating given on Tuesday, December 8 by Sidoti.

Since August 9, 2017, it had 0 insider purchases, and 5 insider sales for $4.80 million activity. The insider FARAHI BEN sold 18,600 shares worth $813,990. 34,000 shares valued at $1.17M were sold by FARAHI BOB on Wednesday, August 9.

Investors sentiment increased to 1.34 in Q3 2017. Its up 0.20, from 1.14 in 2017Q2. It increased, as 6 investors sold Monarch Casino & Resort, Inc. shares while 32 reduced holdings. 18 funds opened positions while 33 raised stakes. 10.01 million shares or 1.93% more from 9.82 million shares in 2017Q2 were reported. Credit Suisse Ag stated it has 0% in Monarch Casino & Resort, Inc. (NASDAQ:MCRI). Wells Fargo And Company Mn accumulated 49,754 shares or 0% of the stock. State Street reported 0% of its portfolio in Monarch Casino & Resort, Inc. (NASDAQ:MCRI). Ameriprise Inc has 0% invested in Monarch Casino & Resort, Inc. (NASDAQ:MCRI). Hancock owns 6,776 shares or 0.01% of their US portfolio. Eam Lc has invested 0.29% in Monarch Casino & Resort, Inc. (NASDAQ:MCRI). Amer Grp, a New York-based fund reported 8,622 shares. Texas-based Employees Retirement Systems Of Texas has invested 0.01% in Monarch Casino & Resort, Inc. (NASDAQ:MCRI). Bnp Paribas Arbitrage Sa invested in 5,662 shares. Connor Clark And Lunn Invest Management Limited reported 12,025 shares or 0% of all its holdings. Morgan Stanley holds 0% or 45,506 shares. Alliancebernstein Ltd Partnership holds 0% or 17,600 shares in its portfolio. Cornerstone Capital Mgmt Holding Lc holds 0% in Monarch Casino & Resort, Inc. (NASDAQ:MCRI) or 5,200 shares. Swiss National Bank & Trust holds 18,511 shares or 0% of its portfolio. Susquehanna Interest Gru Llp reported 0% in Monarch Casino & Resort, Inc. (NASDAQ:MCRI).

Investors sentiment increased to 1.44 in Q3 2017. Its up 0.35, from 1.09 in 2017Q2. It increased, as 21 investors sold AMAG Pharmaceuticals, Inc. shares while 43 reduced holdings. 35 funds opened positions while 57 raised stakes. 39.98 million shares or 4.47% less from 41.85 million shares in 2017Q2 were reported. Palo Alto Investors holds 2.67% or 3.44M shares in its portfolio. Comerica Bancorp, a Michigan-based fund reported 37,107 shares. Bnp Paribas Arbitrage Sa has 0% invested in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Gotham Asset Mgmt Ltd Liability Corporation reported 431,411 shares. Moreover, State Street Corporation has 0% invested in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). State Of New Jersey Common Pension Fund D reported 66,167 shares stake. Bancorporation Of America Corporation De reported 0% stake. Signalpoint Asset Mgmt Limited Co invested in 0.2% or 21,072 shares. Zebra Ltd Com holds 0.08% or 13,332 shares. California Pub Employees Retirement System stated it has 0% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Bank & Trust Of Montreal Can reported 142,788 shares stake. Gideon Cap Advsrs has invested 0.21% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Voya Ltd Limited Liability Company, a Georgia-based fund reported 61,637 shares. 338 are held by Glenmede Trust Na. Zurcher Kantonalbank (Zurich Cantonalbank) invested in 0% or 1,049 shares.

Among 13 analysts covering AMAG Pharmaceuticals (NASDAQ:AMAG), 3 have Buy rating, 1 Sell and 9 Hold. Therefore 23% are positive. AMAG Pharmaceuticals had 34 analyst reports since August 18, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Friday, September 8 by Morgan Stanley. Morgan Stanley maintained it with “Overweight” rating and $22 target in Friday, November 3 report. The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) earned “Hold” rating by Needham on Wednesday, January 11. The firm has “Outperform” rating by Leerink Swann given on Wednesday, May 4. The rating was initiated by Needham with “Buy” on Thursday, October 27. The firm has “Strong-Buy” rating by Zacks given on Wednesday, August 19. The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) earned “Equal-Weight” rating by Barclays Capital on Thursday, January 21. Cowen & Co downgraded the shares of AMAG in report on Friday, February 3 to “Market Perform” rating. The firm has “Buy” rating by Jefferies given on Wednesday, August 16. The company was maintained on Monday, June 26 by Cantor Fitzgerald.

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, makes, develops, and commercializes therapeutics for women??s health, anemia management, and cancer supportive care in the United States. The company has market cap of $509.39 million. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme , an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. It currently has negative earnings. The firm also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families.

Since August 29, 2017, it had 0 insider purchases, and 1 sale for $20,938 activity. Shares for $20,938 were sold by Vittiglio Joseph on Tuesday, August 29.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>